Therapeutic Area Heritage

A leader in oncology and inflammation

At Amgen, we lead with action. Our world-class inflammation and oncology franchises have a laser-like focus on improving the lives of patients with life-threatening or chronic diseases.

Offering biosimilars for the treatment of these diseases is one way we’re striving to improve patients’ lives. Because of their lower costs, biosimilars may help patients get the medicines they need.1 And that’s a good thing because biologic treatments for oncology and inflammation have changed the outlook for people with these diseases and everyone who cares for them.

Biologics in oncology

At Amgen, we are experts in the science of creating and manufacturing biologics and, now, biosimilar medicines for oncology patients.

Our biologics for cancer treatment include:

  • Immunotherapies
  • A biologic treatment used in the curative setting
  • Targeted therapies
    • These include monoclonal antibodies (mAbs), which revolutionized cancer treatment and continue to constitute an important treatment modality.2

Our oncology portfolio includes:

1

Recently approved biosimilar medicine, and several more in the pipeline3

17

Innovative medicines in different phases of clinical development4

As of December 31, 2018.

Our history with oncology biologics includes not only the discovery, development, and production of these practice-changing medicines, but also our innovative delivery systems to help increase treatment choices and adoption.

Biologics for chronic inflammatory diseases

Biologics for chronic inflammatory diseases, such as moderate to severe rheumatoid arthritis, were a true advance. With their advent, the provider's treatment plan for their patient was no longer just about managing symptoms, but about potentially putting the disease into clinical remission by inhibiting specifically targeted biochemical pathways of inflammation.5

Amgen has been at the forefront of biologic medicines for inflammation for over 20 years. Now we have a pipeline that is rich in biosimilars that treat inflammation.4

References: 1. Boccia R, Jacobs I, Popovian R, de Lima Lopes G Jr. Can biosimilars help achieve the goals of US health care reform? Cancer Manag Res. 2017;9:197-205. 2. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22:3-13. 3. US Food and Drug Administration. FDA Approves First Biosimilar for the Treatment of Cancer. www.fda.gov/newsevents/newsroom/pressannouncements/ucm576112.htm. Published September 14, 2017. Accessed January 10, 2019. 4. Amgen. Amgen Pipeline. www.amgenpipeline.com/pipeline/. Accessed January 10, 2019. 5. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77-87.

Next: highly specialized knowledge

previous: Worldwide
Biologics leader